Program

Preliminary Program – PIVAC-24

(as of March 1, 2024)

DAY 1 (Thursday, September 26)

1 – Vaccines and Cellulars (I)

8:15 – 8:30 Welcome

8:30 – 9:00 Vaccines and T-cell therapy in solid cancers
(Else Maria Inderberg)

9:00 – 9:30 Personalized cancer vaccines come of age
(Hans-Georg Rammensee)

9:30 – 10:00 Improving the efficacy of dendritic cell vaccines
(Daniel Smrž or Dmitry Stakheev)

10:00 – 10:15 Coffee Break

1 – Vaccines and Cellulars (II)

10:15 – 10:45 Salvage peptide vaccination in checkpoint resistant lung
cancer
(Marij Welters)

10:45 – 11:15 Melanoma vaccines: Survival benefit and New directions
(Craig Slingluff)

11:15 – 11:45 Lipid nanoparticle-formulated mRNA as cancer therapy
(Damya Laoui)

11:45 – 12:15 2 Selected Orals

12:15 – 13:15 Lunch

2 – Determinants and Predictors

13:15 – 13:45 Improving cell therapy of cancer by predicting and
overcoming tumor induced immune suppression
(Stina Wickström)

13:45 – 14:15 Predictive biomarkers for a therapeutic vaccine in prostate
cancer
(Costas Baxevanis)

14:15 – 14:45 Determinants of therapeutic responses to immunotherapy
in patients presenting with TLS
(Wolf Fridman)

14:45 – 15:15 Tumor HLA class I alterations: detection and clinical
relevance
(Natalia Aptsiauri)

15:15 – 15:30 Coffee Break

3 – Checkpoints

15:30 – 16:00 Immune cell dynamics predicting clinical responses to
checkpoint blockade in melanoma
(Graham Pawelec)

16:00 – 16:30 Glyco-immune checkpoints for Immunotherapy of cancer
(Gosse Adema)

16:30 – 17:00 The exercise of tinkering with the immune system
(Per Thor Straten)

17:00 – 17:15 Coffee Break

17:15 – 17:45 Challenges of immune-oncology drug development in post
checkpoint inhibitor era
(Radek Spisek)

17:45 – 18:15 2 Selected Orals

DAY 2 (Friday, September 27)

4 – Tumor (Immnune) Microenvironment and Resistance (I)

8:30 – 9:00 Immune evasion in pancreatic cancer
(Enzo Bronte)

9:00 – 9:30 Immunological configuration of ovarian carcinoma: The
impact on disease outcome and response to
Immunotherapy
(Jitka Palich Fucikova)

9:30 – 10:00 Smoldering inflammation and collagen remodeling
condition the tumor microenvironment immunity
(Luca Vannucci)

10:00 – 10:15 Coffee Break

5 – Tumor (Immnune) Microenvironment and Resistance (II)

10:15 – 10:45 Myeloid cells en-RAGE antitumor immunity
(Sue Ostrand-Rosenberg)

10:45 – 11:15 A novel, radiotherapy actionable immunological
mechanism of resistance to CDK4/6 inhibitors in HR+
breast cancer
(Lorenzo Galluzi)

11:15 – 11:45 Exploring CSPG4 immune-targeting in osteosarcoma
using comparative oncology models
(Federica Cavallo)

11:45 – 12:15 2 Selected Orals

12:15 – 13:15 Lunch

6 – New Targets and Approaches

13:15 – 13:45 Increased complexity of immune escape mechanisms of
tumors
(Barbara Seliger)

13:45 – 14:15 New targets for the treatment of acute leukaemia
(Barbara-Ann Guinn)

14:15 – 14:45 Targeting of MDSC to improve tumor immunotherapy
(Viktor Umansky)

14:45 – 15:15 Tolerogenic onco-fetal proteins as emerging targets for
novel therapies
(Joerg Wischhusen)

15:15 – 15:30 Coffee Break

7 – Strategies

15:30 – 16:00 Dissection of the T-cell response in pancreatic cancer at
the single cell level
(Rienk Offringa)

16:00 – 16:30 Harnessing the pleiotropy of TGF-β to treat diseases
associated with immune dysfunction
(Sophie Lucas)

16:30 – 17:00 What is an effective T cell receptor avidity for tumor
rejection in vivo?
(Pramod Srivastava)